NEW YORK, May 03, 2018 (GLOBE NEWSWIRE) -- The global tuberculosis drugs market was estimated at USD 1,046 million in 2017 and is expected to reach USD 1,432 million in 2024 at a CAGR of 4.6% during the forecast period. Factor driving the market are increasing number of TB patients, rising awareness among people, and growing number of research and development activities in novel drug developments. Moreover, technological advancement in early stage detection, and government & non-government organizations initiatives to promote TB drugs are further augmenting the growth of the market. However, some adverse drug reaction to the body may inhibit the market growth.
TB is caused by the Mycobacterium tuberculosis bacteria and is highly contagious disease. It is caused by inhaling tuberculosis bacilli in the air. According to the World Health Organization (WHO) in 2016, about 10.4 million people across the globe became infected with it. In developing countries, tuberculosis remains a significant cause of both illness and death. TB is second to HIV as the leading infectious killer of the adults worldwide. Apart from its health consequences, there are many economic impact of the disease which is staggering, making TB a major contributor to poverty.
Asia Pacific and Africa leads in Tuberculosis drugs market
Asia-Pacific holds the maximum share of the market, due to growing number of TB patients in countries such as India and China, as well as its high incidence rate in this region. There are almost 47% of multi-drug-resistant tuberculosis (MDR-TB) cases in China, and India. In Middle East and Africa, the growth of the market is due to growing number of new TB patients every year and increasing prevalence of the disease. Mostly, the cases of TB are found amongst the age group of 15-49 years. According to WHO, billions of investment is needed for research and developments. This investment would significantly improve the market in future.
Browse full research report with TOC on “Global Tuberculosis Drugs Market Outlook, Trend and Opportunity Analysis, Competitive Insights, Actionable Segmentation & Forecast 2024” at: https://www.energiasmarketresearch.com/global-tuberculosis-drugs-market-report/
To purchase report: sales@energiasmarketresearch.com
Key findings from the report:
- On the basis of drugs class, the first-line anti-TB drugs segment held the major of the market owing to the growing demand in developing countries, and growing research and development activities. Also because first-line anti-TB drugs are the first and foremost drugs used to treat the patients.
- Based on the distribution channel, the hospital segment held the major share of the market in 2017
- Incidences of tuberculosis is mostly high in Africa and Asia
- Some of the key companies operating in the market include Bayer AG; Lupin Limited; GlaxoSmithKline plc.; Zydus Cadila; Pfizer Inc.; Sanofi; Novartis AG; AstraZeneca; Merck & Co., Inc.; Sandoz International GmbH, and among others
By Type
- Active Tuberculosis
- Latent Tuberculosis
By Drugs Class
- First-line anti-TB drugs
- Isoniazid
- Ethambutol
- Pyrazinamide
- Rifampicin
- Rifabutin
- Streptomycin
- Others
- Second-line anti-TB drugs
- Cycloserine
- Moxifloxacin
- Gatifloxacin
- Amikacin/Kanamycin
- Ethionamide
- Capreomycin
- Others
- Combination drugs
By Distribution Channel
- Retail Pharmacy
- Hospital Pharmacy
- Others
By Region
- North America
- Europe
- Asia-Pacific
- Latin America
- Middle East and Africa
About Energias Market Research Pvt. Ltd.–
Energias Market Research Pvt. Ltd. publishes high quality reports, in-depth market research studies, to help clients obtain investment level clarity on current business scenario, trends and segmentation for their future developments. We are committed to our client’s needs, by providing high quality custom reports solutions best fit for strategy development and implementation to high return of invest (RoI). We believe that exceptional problems need expertise to solve, and with the help of our industries expertise we are able to offer an in depth understanding of what’s crucial, what’s applicable, and what it takes to ensure accomplishment in any business or venture.
With a wide range of expertise from various industrial sectors and more than 50 industries that includes energy, chemical and materials, information and communication technology, semiconductor and electronics industries, healthcare and daily consumer goods, etc. We strive to provide our clients with a one-stop solution for all research and consulting needs.
Contact:
Alan Andrews
Business Development Manager
Phone: +1-716-239-4915
For any queries email us: info@energiasmarketresearch.com
To purchase report: sales@energiasmarketresearch.com